Position
Fidelity in Krystal Biotech, Inc.
Back to the book · All holders of KRYS
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $495.8M$258.32 → $371.67
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 4.35M | $1.07B | — | — | — | 0.1% |
| Q1 2026 | 4.37M | $1.13B | $258.32 | $51.2M | $6.29M | 0.1% |
| Q2 2026 | 4.42M | $1.64B | $371.67 | $495.8M | $16.4M | 0.1% |